Roxadustat for the treatment of anemia in patients with <scp>lower‐risk</scp> myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 studyDavid H. Henry, Kin-Hung P. Yu, Charles W. Bradley et al.|American Journal of Hematology|2021Cited by 58
Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)David H. Henry, Kin-Hung P. Yu, John A. Glaspy et al.|Blood|2019Cited by 23
Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin LevelsDavid H. Henry, Peony Yu, Robert Leong et al.|Blood|2020Cited by 6